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INTRODUCTION 
 
Transporters play an important role in the drug disposition through their involvement 
in the pathways of drug absorption, distribution and excretion. Transporters would be 
determinants of the pharmacological and/or toxicological effect of drugs when they 
regulate the distribution of drugs to tissues which is responsible for their expression of 
efficacy and/or toxicity. For example, the liver-specific uptake process of 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) by organic anion 
transporters is necessary to achieve their optimal efficacy. In addition, the uptake into 
hepatocytes from the portal vein is a prerequisite step for subsequent metabolism and/or 
biliary excretion for hepatic eliminating substances. This uptake process could be the 
rate limiting step of the hepatic clearance of the substrates if permeability-surface area 
product of back efflux from hepatocytes to blood was lower than sum of intrinsic 
clearance of metabolism and biliary excretion [1,2]. 
Solute carrier organic anion transporter family, member 1B1 (OATP1B1, gene 
SLCO1B1), is specifically expressed at the basolateral membrane of hepatocytes [3] and 
plays a crucial role in the hepatic uptake of structurally divergent endogenous and 
exogenous substances [4]. In recent years, many clinically useful drugs have been 
reported as substrates of OATP1B1 (i.e. atorvastatin [5], simvastatin [6], valsartan [7], 
pravastatin [8]). Subsequently, several cases of in vivo drug-drug interaction which were 
likely occurred at OATP1B1 have been reported in the combination therapy of statins 
and cyclosporine [9,10]. For example, coadministration of cerivastatin with 
cyclosporine in kidney transplant recipients resulted in a 3- to 5-fold increase in 
cerivastatin and its metabolites plasma concentrations [9], and this drug-drug interaction 
was partly explained by in vitro study in which cyclosporine effectively inhibited the 
OATP1B1-mediated cerivastatin uptake [11]. Therefore, the interaction between 
OATP1B1 and drugs are certainly important issue for drug treatment as is the case of 
cytochrome P450. 
On the other hand, polymorphisms of SLCO1B1 gene are also important issue, since 
OATP1B1-mediated uptake can be rate-determining step for hepatic clearance of drugs. 
Polymorphisms of SLCO1B1 gene have been reported in Caucasians [12,13,14], African 
Americans [12], Japanese [15,16] and other Asians [17]. These reports showed the 
existence of more than twenty haplotypes at the SLCO1B1 locus which showed 
remarkable ethnic differences. Phenotypes of OATP1B1 variants have been 
characterized in vivo by using pravastatin as a probe drug [16,13,18,19, 20,21,22]. 
These studies have shown the impact of the SLCO1B1 polymorphism on pravastatin 
pharmacokinetics in humans, and that especially the c.521T>C single nucleotide 
-    - 3 
polymorphism (SNP) seems to be an important determinant of pravastatin disposition 
[13,16,19,20,22]. However, there are conflicting reports that hepatic uptake of 
pravastatin was accelerated in subjects harboring the c.388A>G SNP whereas little 
effect was observed in subjects with c.521T>C SNP [18,21]. Therefore, studies on 
correlation between genotype, involving promoter region, and phenotype should be 
demonstrated to verify the determinant-SNP(s) on the drug disposition. 
In parallel with in vivo studies, functional characterization of some OATP1B1 
variants have been performed in several laboratories by using in vitro expression 
systems [12,15,23,24,25]. Michalski et al. [23] showed that the level of 
bromosulfophthalein and cholyltaurine transport activities of OATP1B1*1a were higher 
and lower than those of OATP1B1*1b, respectively, that contained c.388A>G SNP and 
was the major allele in African American [12] and Asians [15,16,17]. In analyses of 
c.521T>C SNP function, different results have been obtained by different methods. 
Tirona et al. [12] and Nozawa et al. [25] showed that the level of transporting activity of 
OATP1B1*5 (c.521T>C) expressed in HeLa cells or Xenopus oocytes was decreased as 
compared with OATP1B1*1a. In contrast, Nozawa et al. [15] and Iwai et al. [24] 
reported that no decrease in transporting activity of OATP1B1*5 was found when this 
variant protein was expressed in HEK293 cells. Therefore, effects of c.388A>G SNP 
and c.521T>C SNP on the function of OATP1B1 remain controversial, and the 
functional characterization of OATP1B1 variants are required to precisely explain the 
interindividual variability in the pharmacokinetics accompanied by the SLCO1B1 
haplotypes. 
The purpose of the present study was to elucidate the function and roles of OATP1B1 
in the membrane penetration of drugs by using in vitro expression systems. In the 
chapter I, we examined the functional characterization of eight OATP1B1 variant alleles, 
which are made of a combination of c.388A>G, c.521T>C and c.1007C>G, and effects 
of those variants on the transport of statins. In chapter II, we examined the interactions 
between OATP1B1 and anticancer agents to evaluate whether OATP1B1-mediated 
transport process is a major determinant of the hepatic clearance of the anticancer drugs, 
and effects of SLCO1B1 polymorphisms on the transport of the anticancer drugs were 
also estimated. 
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Chapter I 
 
Studies on the effect of SLCO1B1*1b and *15 on 
the uptake of HMG-CoA reductase inhibitors 
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I-I: Introduction 
 
Recently, Morimoto et al. [26] have shown that there is a significant association 
between statin-induced myopathy and SLCO1B1*15 (c.388A>G and c.521T>C) in 
patients with hypercholesterolemia who had been treated with pravastatin or atorvastatin 
in case-control study. There are many causes of myopathy and rhabdomyolysis, which 
are classified into inherited and acquired type [27]. Toxins and a diverse spectrum of 
drugs play a role in up to 80% of adult cases of acquired rhabdomyolysis [27] and 
statins have involved in most cases of myopathy and rhabdomyolysis in recent years 
[28]. Although the fundamental mechanism of statin-induced myotoxicity is not 
completely understood, it has been thought that myopathy and its possible progression 
to rhabdomyolysis is associated with dose or plasma concentration of statins [29,30,31]. 
In fact, the risk of muscle toxicity caused by statins has been reported to increase when 
statins are coadministered with other drugs that increase the plasma concentrations of 
statins [32]. Therefore, the increased systemic exposure of statins caused by 
polymorphism(s) of the gene responsible for the disposition of statins may explain 
interindividual variations in response to statins such as a myotoxicity. Accordingly, the 
study reported by Morimoto et al. [26] suggested that statins exposure in systemic 
circulation would rise in subjects possessing SLCO1B1*15 allele. In support of this, 
several groups [13,16,19,20,22] reported that SLCO1B1*5, *15 and *17 significantly 
increased the area under the plasma concentration-time curve (AUC) of pravastatin. 
In regard to the function of OATP1B1*5 and *15, however, contradictory results 
have been reported by using in vitro expression systems. Tirona et al. [12] first reported 
that OATP1B1*5, containing c.521T>C SNP, reduced the level of transporting activity 
of OATP1B1 expressed in HeLa cells whereas Nozawa et al. [15] and Iwai et al. [24] 
reported that OATP1B1*5 did not alter the transporting activity of OATP1B1 when it 
was expressed in HEK293 cells. This conflicting result could be explained with the cell-
line-dependent intracellular sorting of OATP1B1 variant proteins. A sorting error of 
OATP1B1*5 variant protein occurred in HeLa cells [12], while OATP1B1*5 [15,24] 
and *15 [24] variant proteins appropriately expressed at basolateral membrane in 
HEK293 cells. Therefore, the effects of c.521T>C SNP on the function of OATP1B1 
remains controversial. 
Morimoto et al. [26] reported that a novel haplotype of SLCO1B1*15+C1007G, an 
allele possessing c.1007C>G in addition to the mutation of SLCO1B1*15, was found in 
a Japanese patient with hypercholesterolemia who experienced muscle pain and loss of 
muscle strength after taking pravastatin. Tirona et al. [12] showed that nonsynonymous 
amino acid substitution localized on the putative transmembrane-spanning domain of 
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OATP1B1 were associated with significant reduction in the level of transporting 
activities. Since c.1007C>G mutation causes a substitution of a proline to an arginine 
residue at position 336 in OATP1B1 that is putatively located on transmembrane-
spanning domain 7 [16], it is possible that the transporting function of OATP1B1 
harboring this substitution is impaired. 
In the present study, we examined the effects of SLCO1B1*1b, *5 and *15 on the 
functional properties of OATP1B1 by using transient expression systems in HeLa and 
HEK293 cells with typical substrates of OATP1B1, estradiol 17β-D-glucuronide and 
estrone 3-sulfate. We also examined the effects of c.1007C>G mutation found in a novel 
allele of SLCO1B1*15+C1007G. In addition, we studied the effects of these variant 
alleles on the transporting activity of OATP1B1 for pravastatin, atorvastatin, 
cerivastatin and simvastatin using a HPLC tandem mass spectrometry. The effects of 
these variant alleles on the intracellular localization of OATP1B1 protein in HeLa and 
HEK293 cells were also studied. 
 
 
I-II: Materials and Methods 
 
Reagents 
 
[3H] Estrone 3-sulfate ammonium salt (1702 GBq/mmol) and [3H] estradiol 17β-D-glucuronide 
(1498.5 and 1665 GBq/mmol) were purchased from PerkinElmer Life Science, Inc. (Boston, MA). 
Zero Blunt TOPO PCR Cloning Kit and pcDNA3.1/Zeo were obtained from Invitrogen (Carlsbad, 
CA). Pravastatin, atorvastatin, cerivastatin and simvastatin were kindly donated by Sankyo Co. 
(Tokyo, Japan). Rabbit anti-human LST-1 (OATP1B1) antibody was purchased from Alpha 
Diagnostic International, Inc. (San Antonio, TX). All other reagents were commercially available 
and of reagent grade. HEK293 cells were obtained from Health Science Research Resources Bank 
(Osaka, Japan). HeLa cells were kindly donated by Dr. Tomohito Kakegawa, Department of 
Biochemistry, Graduate School of Pharmaceutical Sciences, Chiba University. 
 
Full-length cDNA cloning 
 
Full-length human OATP1B1 (also known as LST-1, OATP2 and OATP-C, gene SLC21A6 and 
SLCO1B1) coding sequences corresponding to nucleotides 67-2247 of GeneBank accession No. 
AF205071 was amplified from human liver cDNA using the primer pair 5’-AATCCAGGTGATTG-
TTTCAAACTGAGCATC-3’ (forward) and 5’-TGGAAACACAGAAGCAGAAGT-3’ (reverse). 
The polymerase chain reaction (PCR) was performed using KOD-Plus-DNA polymerase (Toyobo, 
Osaka, Japan) according to the following schedule: 2-min denaturation/activation at 94°C, followed 
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by 3 cycles with 30-sec denaturation at 94°C, 30-sec annealing at 66°C, 90-sec elongation at 68°C, 3 
cycles with 30-sec denaturation at 94°C, 30-sec annealing at 63°C, 90-sec elongation at 68°C, 3 
cycles with 30-sec denaturation at 94°C, 30-sec annealing at 60°C, 90-sec elongation at 68°C, 3 
cycles with 30-sec denaturation at 94°C, 30-sec annealing at 57°C, 90-sec elongation at 68°C, and, 
subsequently, 28 cycles with 30-sec denaturation at 94°C, 30-sec annealing at 54°C, 105-sec 
elongation at 68°C, and a final elongation at 68°C for 3 min. The amplicon was subcloned into pCR-
Blunt II-TOPO vector and the sequence was verified as coding OATP1B1*1b using dye terminator 
sequencing (CEQ2000XL DNA Analysis System, Beckman Coulter, Inc., Fullerton, CA). 
OATP1B1*1b cDNA, located between Kpn I and Not I multiple cloning sites, was subcloned into 
pcDNA3.1/Zeo. 
 
Site-directed mutagenesis 
 
Point mutations were introduced into OATP1B1*1b/pcDNA3.1/Zeo using KOD-Plus DNA 
polymerase followed by digestion of the template DNA with Dpn I. Oligonucleotides containing 
c.388A>G and c.521T>C were used to create OATP1B1*1a and OATP1B1*15 expression vectors, 
respectively. The c.521T>C substitution was also introduced into OATP1B1*1a vector in order to 
create OATP1B1*5 expression vector. Similarly, c.1007C>G mutated vectors were constructed from 
OATP1B1*1a, OATP1B1*1b, OATP1B1*5 and OATP1B1*15 vectors. The presence of the 
mutations was verified by full sequencing. Obtained OATP1B1 variant vectors are shown in Table 1. 
 
Table 1.  SLCO1B1 allelic variants prepared by site-directed mutagenesis 
Mutations (amino acid substitution) SLCO1B1 
allelic 
variants 
c.388A>G 
(Asn130Asp) 
c.521T>C 
(Val174Ala) 
c.1007C>G 
(Pro336Arg) 
*1a A T C 
*1b G T C 
*5 A C C 
*15 G C C 
*1a + C1007G a A T G 
*1b + C1007G a G T G 
*5 + C1007G a A C G 
*15 + C1007G G C G 
a These alleles have not been reported as naturally occurring variants. 
 
Primers used for site-directed mutagenesis were as follows: 388G>A, 5’-GAAACTAATATCAATT-
CATCAGAAAATTC-3’ (forward) and 5’-GAATTTTCTGATGAATTGATATTAGTTTC-3’ 
(reverse); 521T>C, 5’-CATGTGGATATATGCGTTCATGGGTA-3’ (forward) and 5’-TACCCATG-
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AACGCATATATCCACATG-3’ (reverse); 1007C>G, 5’-CATCCTTACTAATCGCCTGTATGTTA-
TG-3’ (forward) and 5’-CATAACATACAGGCGATTAGTAAGGATG-3’ (reverse). The PCR site-
directed mutagenesis was performed under the following conditions: 2-min denaturation/activation 
at 94°C followed by 12 cycles with 20-sec denaturation at 95°C, 30-sec annealing at 50°C and 8-min 
elongation at 68°C. 
 
Cell culture and expression 
 
For transient expression, the transfection of plasmids into HEK293 cells or HeLa cells was 
performed using Lipofectamine 2000 (Invitrogen) or Lipofectamine Plus (Invitrogen), respectively, 
according to the manufacturer’s protocol. Briefly, HEK293 cells seeded at a density of 2-4×105 cells 
per well in a poly-D-lysine coated 12-well plate were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and cells were transfected with 
complexes of 1.5 μg of plasmid and 3 μl of Lipofectamine 2000 reagents diluted in OPTI-MEM I 
(Invitrogen). HeLa cells seeded at 1-1.2×105 cells per well in a 12-well plate were cultured in RPMI 
1640 medium supplemented with 10% FBS and penicillin-streptomycin. At 1 day after seeding, the 
cells were exposed to antibiotics-free DMEM containing serum and then transfected with complexes 
of 0.5 μg of plasmid, 3 μl of Lipofectamine and 2 μl of Plus reagent in DMEM. At 3 h after the 
initiation of transfection, the medium was changed to complete RPMI 1640 medium. At 1 day prior 
to assays, cells were treated with sodium butyrate to enhance the expression of OATP1B1 proteins. 
HEK293 cells and HeLa cells transfected with the pcDNA3.1 vector alone were used to obtain 
background activity (termed mock). The expression of OATP1B1 was verified by reverse 
transcriptase (RT)-PCR. 
 
RT-PCR analysis 
 
Total RNA was extracted by using Trizol reagent (Invitrogen) from transfected cells that had been 
exposed to sodium butyrate for 1 day. After treatment with DNase I (TaKaRa, Kyoto, Japan), cDNA 
synthesis was performed by using Ready-To-Go RT-PCR beads (Amersham Biosciences Corp., 
Piscataway, NJ) with oligo d(T)12-18 primers and 1 U of RNaseOUT (Invitrogen) according to the 
manufacturer’s protocol. Then, the PCR reaction was performed using Ex-Taq (TaKaRa) as follows: 
2-min denaturing at 94°C, 37 cycles with 15-sec denaturing at 94°C, 30-sec annealing at 49°C, 40-
sec elongation at 72°C, and a final elongation for 1 min at 72°C. The specific primer pairs for 
OATP1B1 designed by Tamai et al. [33] and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) 
were as follows: OATP1B1, 5’-TGTCATTGTCCTTTTACCTATTAT-3’ (forward) and 5’-TGTAAG-
TTATTCCATTGTTTCCAC-3’ (reverse); GAPDH, 5’-TGCACCACCAACTGCTTA-3’ (forward) 
and 5’-GGATGCAGGGATGATGTTC-3’ (reverse). Products were run with 3% agarose gel. 
OATP1B1*1b/pcDNA3.1 vector and distilled water were used as templates for positive and negative 
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controls, respectively. 
 
Transport assays 
 
For transport assays, the transfected cells in 12-well plates were treated with sodium butyrate for 
1 day. The medium was changed to DMEM free from both antibiotics and serum without a substrate. 
To assess transporting activity, the medium was removed and the same medium containing a 
substrate was added. The monolayers were incubated for 1-5 min depending on the substrate, and 
then cells were rapidly washed once or twice with ice-cold DMEM containing 5% FBS and three 
times with ice-cold DMEM. For 3H-labeled substrates, cells were lysed in 500 μl of 0.2% SDS, and 
400-μl aliquots were transferred to scintillation vials and 25-μl aliquots of cell lysate were used to 
determine protein concentrations by the method of Lowry with bovine serum albumin (BSA) as a 
standard. Radioactivity was measured by a liquid scintillation counter (LSC 6100, Aloka Co., Tokyo, 
Japan). For un-radiolabeled substrates, 500 μl of ice-cold solution consisting of sodium acetate (pH 
4.5; 10 mM)-acetonitrile-methanol (2:1:1, v/v/v) was added, and the solution containing cells was 
transferred to a centrifuge tube and then the substrate accumulated in cells was extracted by 
sonication for 10 min at 4°C. After centrifugation at 17,000 × g for 10 min at 4°C, a 400-μl aliquot 
of the supernatant was transferred to Ultrafree-MC (Millipore, Billerica, MA) and filtered by 
centrifugation at 5,000 × g for 5 min at 4°C, and the obtained filtrate was stored at -80°C until 
quantitation. To the cell pellet, 400 μl of 0.1N NaOH was added and solubilized, and then a 25-μl 
aliquot of cell lysate was used to determine protein concentration by the method of Lowry with BSA 
as a standard. Transport for estradiol 17β-D-glucuronide and estrone 3-sulfate was determined after 
3 and 1 min of incubation, periods within which uptake rate was not saturated, with concentrations 
of 500 nM and 50 nM at 37°C, respectively. The uptake rate was estimated by subtracting uptake by 
mock cells from total uptake by OATP1B1 cDNA-transfected cells and expressed as a percentage of 
OATP1B1*1a (reference allele). For transport assay of statins, preliminary study was carried out to 
estimate IC50 values of statins by examining the transporting activity for estradiol 17β-D-
glucuronide and estrone 3-sulfate substrate in the absence or presence of various concentrations of 
statins. IC50 values estimated were: approximately 10 μM for atorvastatin and cerivastatin and 
approximately 100 μM for pravastatin and simvastatin. Thus, the substrate concentrations in the 
transport medium were set at 20 μM for pravastatin, 0.5 μM for atorvastatin and cerivastatin, and 10 
μM for simvastatin so that the substrate concentrations would be lower than those at which half the 
maximal uptake occurs (Km). The incubation period for pravastatin was set at 5 min and the 
incubation periods for atorvastatin, cerivastatin and simvastatin were set at 1 min in order to 
determine the initial uptake rate. The uptake rate was expressed as cell-to-medium ratio, which was 
estimated by dividing the amount of statins accumulated in cells by the substrate concentration in the 
transport medium. 
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Kinetic analysis 
 
Transport for pravastatin and atorvastatin was determined after 5 and 1 min of incubation with 5, 
10, 20, 50 and 100 μM and with 0.5, 2, 5, 20 and 50 μM at 37°C, respectively. The OATP1B1-
mediated uptake was calculated after subtracting the uptake by the mock cells from the uptake by 
OATP1B1 cDNA-transfected cells at each concentration. Michaelis-Menten-type nonlinear curve 
fitting was carried out to obtain kinetic parameters of the maximal uptake rate (Vmax) and Km 
(DeltaGraph 4.5, RockWare Inc., Golden, CO). 
 
Analytical procedures for 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) 
 
Quantitation of statins was performed using HPLC tandem mass spectrometry. The HPLC system 
consisted of three LC-10ADVP pumps, a SLC-10AVP controller, a SIL-HTC auto-injector and a FCV-
12AH switching valve (Shimadzu, Kyoto, Japan). The HPLC column used was a CAPCELL PAK 
C8 UG120 (5 μm in particle size, 4.6 × 35 mm, Shiseido, Tokyo, Japan). Aliquots (pravastatin, 100 
μl; atorvastatin, cerivastatin, simvastatin, 10 μl) of samples were injected onto the column with the 
mobile phase consisting of methylammonium acetate (pH 4.5; 1 mM)-acetonitrile-methanol 
(70:15:15; v/v/v) (Eluate C) at a flow rate of 1.2 ml/min. After 1 min, the mobile phase was changed 
to a mixture of methylammonium acetate (pH 4.5; 1 mM)-acetonitrile-methanol (30:35:35; v/v/v) 
(Eluate A) and methylammonium acetate (pH 4.5; 1 mM)-acetonitrile -methanol (10:45:45; v/v/v) 
(Eluate B) at a flow rate of 0.5 ml/min using a gradient program described below, and the eluate was 
taken into the mass spectrometer. After 5 min, the solvent was switched to Eluate C to re-equilibrate 
the column. The time program of the mixture ratio of eluate A and eluate B was set as follows: 0% B 
for 0-1.2 min, linear gradient from 0 to 100% B for 1.2-3.5 min, 100% B for 3.5-4.7 min, linear 
gradient from 100 to 0% B for 4.7-4.8 min, and then 0% B for 4.8-7.0 min. The analytes were 
detected by an API4000 mass spectrometer with a turbo-ion spray interface (Applied Biosystems, 
Foster, CA). All analytes were detected in positive mode, and the precursor to product ions 
monitored were m/z 447.3 > m/z 327.3 (pravastatin), m/z 559.3 > m/z 440.4 (atorvastatin), m/z 
460.3 > m/z 356.1 (cerivastatin), and m/z 441.3 > m/z 325.3 (simvastatin). Samples for calibration, 
validation and quality control were prepared in a manner similar to that used for preparation of 
analytical samples described above. Briefly, untransfected HEK293 cells seeded on a 12-well plate 
were washed three times with ice-cold DMEM, and extraction solution spiked with known amounts 
of standards was added. Then the following procedures (i.e., extraction and filtration) were carried 
out. The quantitative range of analytes was determined by intra-day reproducibility assays in which 
the limit of quantitation was set at 0.25 nM for pravastatin, atorvastatin and cerivastatin and at 2.5 
nM for simvastatin, as these were sufficient to estimate the lowest concentrations at which 
acceptable accuracy (< 100 ± 20%) and imprecision (< ±20%) were obtained. 
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Immunofluorescence microscopy 
 
Transfected cells were grown on chamber slides (Nalge Nunc International, Naperville, IL). 
Sodium butyrate was added to the culture medium 1 day before the experiment. After washing twice 
with PBS, the monolayers were fixed with 4% formaldehyde in PBS. After rinsing cells with PBS, 
the cells were incubated with 0.05% Tween 20 in PBS (PBS-T) containing 3% BSA for 30 min at 
room temperature for blocking. The monolayers were incubated with the previously described 
primary antibody against OATP1B1 (1:50-fold in PBS-T) for 1 h at room temperature. Cells were 
washed four times with PBS-T and then incubated with PBS-T containing goat anti-rabbit IgG 
labeled with Alexa Fluor 488 (Molecular Probes, Inc., Eugene, OR) for 1 h at room temperature. 
After washing cells twice with PBS-T, about two drops of ProLong Antifade reagent/mounting 
mixture (Molecular Probes) were added to the slide. Confocal laser-scanning immunofluorescence 
microscopy was performed using FluorView FV-500 (Olympus, Tokyo, Japan). 
 
 
I-III: Results 
 
Expression of OATP1B1 in HEK293 and HeLa cells 
 
Levels of OATP1B1 mRNA transiently expressed in HEK293 and HeLa cells were 
analyzed by RT-PCR. As shown in Fig. 1, the levels of mRNA were apparently equal 
among OATP1B1*1a and variants in either of HEK293 or HeLa cells. 
 
(A) HEK293                            (B) HeLa 
 
 
 
 
 
 
 
Fig. 1.  RT-PCR analysis of mRNA expression of (A) OATP1B1 and GAPDH in HEK293 cells 
and (B) OATP1B1 and GAPDH in HeLa cells transiently expressing OATP1B1 variants. 
Specific bands corresponding to OATP1B1 and GAPDH are shown with sizes of 194 and 177 
base pairs, respectively. 
M, marker; NC, negative control; PC, positive control; 1, mock; 2, OATP1B1*1a; 3, OATP1B1*1b; 4, OATP1B1*5; 
5, OATP1B1*15; 6, OATP1B1*1a+C1007G; 7, OATP1B1*1b+C1007G; 8, OATP1B1*5+C1007G; 9, OATP1B1*15 
+C1007G. 
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Transport activity of SLCO1B1 allelic variants for typical substrates 
 
The relative transporting activities of the SLCO1B1 allelic variants for estradiol 17β-
D-glucuronide and estrone 3-sulfate are shown in Fig. 2. The transporting activities for 
these typical substrates of OATP1B1 significantly decreased in either HEK293 and 
HeLa cells expressing OATP1B1*5, *15, *5+C1007G and *15+C1007G. The extents of 
decrease were not greatly different among these variants, ranging from -37% to -73% of 
that of OATP1B1*1a. In contrast, there was no apparent tendency of changes in the 
activities of cells expressing OATP1B1*1b, *1a+C1007G and *1b+C1007G, which 
ranged from 85% to 130% of that of OATP1B1*1a. 
 
(A) HEK293                            (B) HeLa 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.  Uptake of [3H] estradiol 17β-glucuronide (closed bars) and [3H] estrone 3-sulfate (open 
bars) into (A) HEK293 cells and (B) HeLa cells transiently expressing SLCO1B1 allelic variants. 
Each bar represents the mean and S.D. of three independent assays. *P < 0.05, **P < 0.01, ***P < 0.001 significantly 
different from the uptake by OATP1B1*1a. 
 
Transport activity of SLCO1B1 allelic variants for statins 
 
Since the effects of OATP1B1 variants on activities for the uptake of typical 
substrates of OATP1B1 were similar in HEK293 and HeLa cells, the effects of these 
valiant alleles on the transport of statins were studied using only HEK293 cells. Similar 
to the results for typical substrates of OATP1B1, transporting activities for pravastatin, 
atorvastatin and cerivastatin decreased significantly in HEK293 cells expressing 
OATP1B1*5, *15, *5+C1007G and *15+C1007G, whereas those of OATP1B1*1b, 
*1a+C1007G and *1b+C1007G were not apparently different from that of OATP-
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1B1*1a (Figures 3, A, B and C). However, the extents of decreases in the activities of 
cells expressing OATP1B1*5, *15, *5+C1007G and *15+C1007G appeared to be 
different among statins when they were compared with the activity of OATP1B1*1a. 
 
(A) Pravastatin                          (B) Atorvastatin 
 
 
 
 
 
 
 
 
 
 
 
 
(C) Cerivastatin                          (D) Simvastatin 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.  Uptake of (A) pravastatin, (B) atorvastatin, (C) cerivastatin, and (D) simvastatin into 
HEK293 cells transiently expressing SLCO1B1 allelic variants. 
Each bar represents the mean and S.D. of triplicated determinations. 
 
The most prominent decrease was found for pravastatin followed by atorvastatin and 
cerivastatin. In contrast, a tendency of decreases such as that found in the typical 
substrates and the three statins was not observed for simvastatin, for which the activities 
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of cells expressing OATP1B1*5 and *15 were not different from that of OATP1B1*1a 
and those of OATP1B1*1a and its variants were comparable or less than that of mock 
(Fig. 3D). 
 
Kinetic analysis 
 
Since the effects of OATP1B1*5, *15 and *15+C1007G on the transporting activity 
of OATP1B1 for statins were most prominent for pravastatin and atorvastatin, the 
effects of OATP1B1*1b, *5, *15 and *15+C1007G on the kinetics of these statins were 
studied using HEK293 cells. As shown in Fig. 4, saturable transport was observed for 
both statins. The kinetic parameters estimated are summarized in Table 2. Although the 
differences were not so apparent for Km values of these statins among the five 
haplotypes studied, the Vmax values of cells expressing OATP1B1*5, *15 and 
*15+C1007G were significantly lower than that of OATP1B1*1a. Accordingly, intrinsic 
clearance (Vmax/Km) of pravastatin and atorvastatin decreased by 79%, 80% and 61% 
and by 67%, 60% and 66% for OATP1B1*5, *15 and *15+C1007G, respectively, as 
compared to OATP1B1*1a. 
 
(A) Pravastatin                          (B) Atorvastatin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.  Concentration dependence of (A) pravastatin and (B) atorvastatin uptake into HEK293 
cells transiently expressing OATP1B1*1a (closed circles), *1b (open circles), *5 (closed 
triangles), *15 (open triangles) or *15+C1007G (closed squares). 
Each value is the mean ± S.D. of at least three independent assays, and the solid lines represent the results of 
nonlinear least-squares analysis. 
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Table 2.  Kinetic parameters of pravastatin and atorvastatin uptake by OATP1B1 variants 
Substrate OATP1B1 variants N 
Km 
(μM) 
Vmax 
(pmol/min/mg) 
Vmax / Km 
(μl/min/mg) 
Pravastatin           
 *1a 5 85.7 ± 29.8 58.2 ± 4.1 0.753 ± 0.291 
 *1b 5 88.7 ± 20.6 61.0 ± 19.0 0.722 ± 0.263 
 *5 5 153 ± 80 22.4 ± 9.0*** 0.155 ± 0.022* 
 *15 4 118 ± 69 17.0 ± 8.1*** 0.154 ± 0.030* 
 *15 + C1007G 5 145 ± 38* 40.8 ± 5.2*** 0.294 ± 0.073* 
Atorvastatin           
 *1a 4 12.4 ± 4.8 70.4 ± 29.9 5.65 ± 0.95 
 *1b 4 12.7 ± 4.5 59.3 ± 10.5 5.01 ± 1.22 
 *5 3 11.1 ± 7.6 16.0 ± 4.3* 1.88 ± 1.16** 
 *15 3 9.29 ± 2.83 19.2 ± 2.4* 2.28 ± 1.08** 
 *15 + C1007G 3 13.1 ± 6.1 23.3 ± 7.4* 1.91 ± 0.59** 
N means numbers of assays; *P < 0.05, **P < 0.01, ***P < 0.001 significantly different from the uptake by 
OATP1B1*1a. 
 
Cell surface expression of SLCO1B1 allelic variants 
 
Since SLCO1B1 allelic variants did not alter either the mRNA levels or Km values of 
statins, the decrease in intrinsic clearance could be derived from the reduced level of 
functional OATP1B1 protein in the plasma membrane. Accordingly, immunocyto- 
 
(A) OATP1B1*1a           (B) OATP1B1*1b            (C) OATP1B1*5 
 
 
 
 
 
(D) OATP1B1*15           (E) OATP1B1*15+C1007G   (F) Mock 
 
 
 
 
 
Fig. 5.  Immunolocalization of (A) OATP1B1*1a, (B) OATP1B1*1b, (C) OATP1B1*5, (D) 
OATP1B1*15, (E) OATP1B1*15+C1007G variant proteins, and (F) mock in HEK293 cells. 
Fluorescent images are shown on the left, and phase contrast images are shown on the right. 
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(A) OATP1B1*1a           (B) OATP1B1*1b            (C) OATP1B1*5 
 
 
 
 
 
(D) OATP1B1*15           (E) OATP1B1*15+C1007G   (F) Mock 
 
 
 
 
 
Fig. 6.  Immunolocalization of (A) OATP1B1*1a, (B) OATP1B1*1b, (C) OATP1B1*5, (D) 
OATP1B1*15, (E) OATP1B1*15+C1007G variant proteins, and (F) mock in HeLa cells. 
Fluorescent images are shown on the left, and phase contrast images are shown on the right. 
 
chemical analysis was performed to examine the cellular localization of OATP1B1 
variants. Fig. 5 shows the staining of OATP1B1 proteins in HEK293 cells transfected 
with OATP1B1*1a, *1b, *5, *15, *15+C1007G and mock vectors. SLCO1B1*1a and 
*1b allelic proteins were mainly localized at the plasma membrane, whereas 
OATP1B1*5, *15 and *15+C1007G variant proteins were observed both in the 
intracellular space and at the plasma membrane. Similar results were also obtained for 
HeLa cells transfected with vectors of these SLCO1B1 allelic variants (Fig. 6). 
 
 
I-IV: Discussion 
 
The results of the present study clearly showed that the transporting activities of 
OATP1B1 for its typical substrates, estradiol 17β-D-glucuronide and estrone 3-sulfate, 
and for three statins, pravastatin, atorvastatin and cerivastatin, decreased significantly in 
HEK293 and/or HeLa cells expressing OATP1B1*5, *15, *5+C1007G and 
*15+C1007G, whereas those of OATP1B1*1b, *1a+C1007G and *1b+C1007G were 
not apparently different from those of OATP1B1*1a (Figures 2, 3 and 4). Since 
SLCO1B1*5 contains c.521T>C and SLCO1B1*15 contains both of c.388A>G and 
c.521T>C, the results suggest that c.521T>C is the key SNP for determining the 
functional alteration of OATP1B1. This contention is in good agreement with the 
present findings that SLCO1B1*5, *15 and *15+C1007G allelic proteins are localized 
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not only at the plasma membrane but also in the intracellular space in both HEK293 
cells (Fig. 5) and HeLa cells (Fig. 6), suggesting that decreased activities of cells 
expressing OATP1B1*5, *15 and *15+C1007G are mainly and commonly derived from 
a sorting error caused by c.521T>C that substitutes a valine to an alanine residue at 
position 174 in OATP1B1, which is putatively located on transmembrane-spanning 
domain 4 [12]. 
The present in vitro findings are consistent with previous in vivo observations that 
AUC of pravastatin was significantly greater in carriers of the haplotype of SLCO1B1*5 
or *15 than that of SLCO1B1*1a or *1b [13,16,19,20,22]. However, the extent of 
decrease in the transporting capacity of OATP1B1 by the mutation of SLCO1B1*5 and 
*15 in vivo is difficult to assess because information on non-renal clearance of 
pravastatin in homozygote of SLCO1B1*5 or *15 is limited. However, the value of 
pravastatin reported in one subject who is homozygous for SLCO1B1*15 was 86 to 87% 
lower and those in heterozygotes of SLCO1B1*15 were 45 to 50% lower than those in 
homozygotes of SLCO1B1*1a or *1b [16]. These values are in good agreement with or 
explainable by the results of the present study showing that Vmax/Km of pravastatin 
uptake in HEK293 cells expressing OATP1B1*15 was 80% and 79% lower than those 
of OATP1B1*1a and *1b, respectively (Table 2). 
Contradicting results have been reported for the influence of OATP1B1*5 on the 
function of OATP1B1 in cDNA-expression systems in which transporting activities of 
cells expressing OATP1B1*5 for estradiol 17β-D-glucuronide and estrone 3-sulfate 
were reduced to less than half of those of OATP1B1*1a when they were transiently 
expressed in HeLa cells [12], whereas the activities for estrone 3-sulfate [15] and 
estradiol 17β-D-glucuronide [24] were not different between OATP1B1*5 and *1a in 
HEK293 cells. The results of the present study showed that transporting activities of 
SLCO1B1*5 allelic protein decreased to less than or around 50% of those of 
SLCO1B1*1a for both estradiol 17β-D-glucuronide and estrone 3-sulfate in HeLa cells 
and even in HEK293 cells, being consistent with results reported by Tirona et al. [12]. 
Therefore, the capacity of SLCO1B1*5 allelic protein is considered to be decreased both 
in vitro [12] and in vivo [13,16,19,20,22], although it remains unknown why there were 
contradicting findings in previous studies. It is possible that such characteristics were 
altered by maintenance conditions such as additional chemicals used for transfection 
and/or sodium butyrate [15] or by clone selection, at which idiosyncratic cell(s) having 
different ability of OATP1B1 sorting might be picked up [23]. 
The results of the present study showed that c.388A>G did not alter the activity of 
OATP1B1 significantly. This contradicts the finding reported by Mwinyi et al. [17] and 
Maeda et al. [20] that the AUC of pravastatin was 60% and 65% smaller in subjects 
-    - 18
carrying SLCO1B1*1b than that in homozygous subjects of *1a, suggesting that uptake 
of pravastatin by OATP1B1 is increased by c.388A>G. Nonetheless, our findings are 
consistent with results of three independent in vitro studies [12,15,23,24,25] and five in 
vivo studies showing that *1b does not affect the activity of OATP1B1 [13,16,19,20,22]. 
Therefore, it is conceivable that c.388A>G does not alter the transporting activity of 
OATP1B1 at least when pravastatin is used as a substrate without the consideration of 
linkage to polymorphisms in promoter region that affect the expression level of 
OATP1B1 protein, although further in vivo study is needed to confirm our and others’ in 
vitro findings [12,15,23,24,25]. The present results also suggest that c.1007C>G does 
not influence the activity of OATP1B1 dramatically, although it substitutes a proline to 
an arginine residue at position 336 in OATP1B1 that is putatively located on 
transmembrane-spanning domain 7. It is notable that c.1007C>G is the first example of 
a nonsynonymous SNP that does not appear to affect the function of OATP1B1 despite 
its localization on a transmembrane-spanning domain. All of the mutations localized on 
the putative transmembrane-spanning domain of OATP1B1 reported previously are 
associated with significant reduction in their transporting activities [12]. 
Of the four statins studied, the most prominent decrease in the activities of cells 
expressing OATP1B1*5 or *15 was found for pravastatin followed by atorvastatin and 
cerivastatin, but no apparent decrease was found for simvastatin when the activities 
were compared with OATP1B1*1a (Figure 3). This tendency may be explained by the 
physicochemical properties of statins. The water/octanol partition coefficients of 
pravastatin, atorvastatin, cerivastatin and simvastatin have been reported to be –0.47, 
1.53, 2.32 and 4.40, respectively [33], which are in the same order as that of less 
decreases in the activities for statins. This phenomenon appears to be derived from the 
extent to which OATP1B1 contributes to the total trans-membrane distribution of statins 
that includes passive diffusion. Comparing the uptake rates in mock among these statins, 
which would express the sum of passive diffusion and active transport in a background, 
the uptake rate of simvastatin was about 20-fold higher than that of atorvastatin and 
cerivastatin and about 10,000-fold higher than that of pravastatin. These findings 
indicate that the transporting activity of OATP1B1 for simvastatin is much less than the 
passive diffusion because of its high lipophilicity. On the other hand, atorvastatin and 
cerivastatin are transported in part by passive diffusion because of their moderate 
lipophilicity, while pravastatin is not transported extensively by passive diffusion 
because of its hydrophilicity. Thus, it is thought that the uptake of pravastatin is affected 
remarkably and the uptake of atorvastatin and cerivastatin is affected moderately by 
mutations carrying c.521T>C. Recently, Lau et al. [34] showed that concomitant 
administration of rifampicin and atorvastatin resulted in 6.8-fold increase of AUC of 
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atorvastatin acid, and lower extent of AUC increase was observed in atorvastatin lactone. 
This result suggested that OATP1B transporters represented the major hepatic uptake 
systems for atorvastatin acid and systemic exposure might be increased in subjects 
carrying functionally deficient variants of OATP1B1. However, further in vivo studies 
are needed to confirm these contentions because these findings were derived from an in 
vitro study and may not reflect the activity of OATP1B1 in vivo. 
The different characteristics between acid and lactone form of statins should be 
considered to estimate the disposition profile especially for the process of tissue 
distribution as statins are chemically and/or biologically in equilibrium between acid 
and lactone form in vivo. The possibility that an acid form of simvastatin that is an 
active form of simvastatin could be transported by OATP1B1 should be noted, although 
the results of the present study suggest that simvastatin (lactone form) is not efficiently 
taken up by OATP1B1. In this regard, the recent study by Pasanen et al. [6] was indeed 
interesting to consider the difference in the disposition of simvastatin acid and lactone. 
The study on the effect of c.521T>C SNP on pharmacokinetics of simvastatin revealed 
that AUC of simvastatin acid was 120 and 221% higher in subjects with the c.521CC 
genotype than in those with the c.521TC and c.521TT genotypes, respectively, and no 
statistically significant association was observed between the SLCO1B1 genotypes and 
the pharmacokinetics of simvastatin lactone [6]. These results stress the importance of 
estimation of rate limiting step in drug clearance and the process of liver distribution 
would be the determinant-step of hepatic clearance for the hydrophilic drug(s) such as 
acid form of pravastatin, atorvastatin and simvastatin. 
The present study showed that the uptake clearances (Vmax/Km) of atorvastatin and 
pravastatin decreased to 20 to 40% of cells expressing OATP1B1*1a and that the uptake 
of cerivastatin at a fixed concentration also decreased to 31 to 69% of OATP1B1*1a in 
the variants of OATP1B1 carrying c.521T>C. Since the allele frequencies of 
SLCO1B1*5 have been reported to be 14%, 2% and 0.7% in European-American, 
African-American and Japanese, respectively [8,13] and those of SLCO1B1*15 have 
been reported to be 10 to 15% in Japanese [13,14], homozygous of c.521C is estimated 
to exist in at least one of 40 to 50 of European-Americans and Japanese. These findings 
suggest that c.521T>C is a major factor influencing the disposition and even efficacy or 
adverse reactions of drugs transported by OATP1B1. For example, it is possible that 
SLCO1B1*5 and *15 may be one of the risk factors attaining adverse drug reactions 
such as myopathy or rhabdomyolysis due to statins which has been reported to be 
dependent on the plasma concentration of statins [20]. In addition, contribution of other 
transporters such as OATP1B3 and OATP2B1 should be considered to estimate the 
effect of SNPs in the SLCO1B1 on hepatic clearance of drugs in vivo. 
-    - 20
In conclusion, the results of current study suggest that c.521T>C is the key SNP that 
causes a sorting error of OATP1B1 and decreases the functional activity of variant 
proteins derived from SLCO1B1*5, *15 and *15+C1007G. 
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Chapter II 
 
The search for anticancer drugs of which uptake 
may be influenced by polymorphisms in 
SLCO1B1 using transient expression system of 
OATP1B1 
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II-I: Introduction 
 
In cancer chemotherapy, patients receive anticancer drug(s) at the dosage near the 
maximum tolerated dose so that the maximum efficacy should be exploited. This makes 
the therapeutic index of cytotoxic chemotherapy agents narrow, and interindividual 
variation in drug exposure may result in less efficacy or fatal adverse reaction. 
Therefore, tailor-made medicine based on pharmacogenetics is required in the oncology 
setting. 
Recently, a study on effect of SLCO1B1 haplotypes on pharmacokinetics of 
irinotecan and its metabolites, SN-38 and SN-38 glucuronide, was demonstrated in 
Asian cancer patients [17]. This study showed that normalized AUC of irinotecan and 
SN-38 in subjects with SLCO1B1*15 haplotype was apparently increased in comparison 
to those without *15, and that there was an inverse association between normalized 
AUC of SN-38 glucuronide and this haplotype [17]. The study also showed that relative 
extent of conversion from irinotecan to SN-38 was not affected by haplotypes whereas 
relative extent of glucuronidation from SN-38 to its glucuronide was apparently 
decreased in subjects with SLCO1B1*15 haplotype [17]. On the other hand, Nozawa et 
al. [25] revealed that SN-38, but not irinotecan, was a substrate of OATP1B1. However, 
the fact that SN-38 exposure increases in patients with SLCO1B1*15 haplotype is 
considerable to be important since the polymorphisms of SLCO1B1 could affect the 
efficacy and/or toxicity in irinotecan therapy. 
Meanwhile, pharmacogenetic effect of SLCO1B1 haplotype on methotrexate 
disposition has not been demonstrated although methotrexate was also found to be a 
substrate of OATP1B1 [12,36]. Although pharmacogenetic studies on cancer 
chemotherapy have been extensively performed on drug-metabolizing enzymes, such as 
thiopurine S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPYD), 
members of the cytochrome P450 family (CYPs), members of the UDP 
glucuronosyltransferase family (UGTs), as well as the ATP-binding cassette transporters, 
P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) [37], there have 
been few studies focusing on the uptake process of hepatic transport [17,38], which led 
to little accumulation of information on the interactions between the hepatic transporters 
and anticancer drugs. 
Since interindividual variability in exposure of anticancer drugs correlates closely 
with efficacy and/or toxicity, it is important to elucidate the key molecule(s) involved in 
pharmacokinetics of anticancer agents in order to evaluate the interindividual variation. 
Among the clinically useful anticancer drugs, chemotherapeutic agents, such as 
anthracyclines, camptothecins, taxanes and vincaalkaloids, eliminate from body mainly 
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via hepatic metabolism and/or biliary excretion. Therefore, it is of great interest whether 
the uptake of the chemotherapeutic agents via OATP1B1 is the rate limiting step for the 
excretion of these drugs, which is an important issue to consider the drug-drug 
interaction and interindividual variation of drug effects and/or toxicity. 
In the present study, inhibition assay was first performed with structurally-diverse 30 
anticancer agents to clarify the interactions between OATP1B1 and the anticancer 
agents. Next, we tested whether potent inhibitors are substrates of OATP1B1 and 
whether polymorphisms in the SLCO1B1 gene affect their membrane penetration. 
 
 
II-II: Materials and Methods 
 
Reagents 
 
[3H] Estrone 3-sulfate ammonium salt (2120.1 GBq/mmol) and [3H] estradiol 17β-D-glucuronide 
(1.67 and 1.96 TBq/mmol) were purchased from PerkinElmer Life Science, Inc. (Boston, MA). [14C] 
Doxorubicin (2.11 GBq/mmol), [3H] vinblastine sulphate (400 GBq/mmol) and [3H] vincristine 
sulphate (248 GBq/mmol) were purchased from Amersham Biosciences (Chalfont St. Giles, UK). 
[14C] Etoposide (1961 MBq/mmol) and [3H] paclitaxel (177.6 GBq/mmol) were purchased from 
Moravek Biochemicals, Inc. (Mercury Lane Brea, CA). Zeocin was obtained from Invitrogen 
(Carlsbad, CA). TaqMan reagents were purchased from Applied Biosystems (Foster, CA). 
Bleomycin, cisplatin, etoposide, flutamide and toremifene were synthesized at Nippon Kayaku Co. 
(Tokyo, Japan). All other reagents were commercially available and of reagent grade. 
 
Vectors 
 
Full-length human OATP1B1 (also known as LST-1, OATP2 and OATP-C, gene SLC21A6, 
SLCO1B1) coding sequences (GeneBank accession No. AF205071) was subcloned into pcDNA3.1 
vector (Invitrogen) as described above. The construction of OATP1B1 variant vectors have been also 
described above. 
 
Cell culture and expression 
 
For permanent expression, HEK293 cells were plated in Dulbecco’s modified Eagle’s medium 
(DMEM) plus 10% fetal bovine serum (FBS) and penicillin-streptomycin in 10-cm dish. The 
pcDNA3.1/OATP1B1*1b or empty vector, termed mock, were transfected into HEK293 cells using 
Lipofectamine Plus (Invitrogen) according to the manufacturer. After 4 weeks of Zeocin selection 
(400 μg/ml), colonies were screened by determining and transporting activity of typical substrates 
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and the expression of OATP1B1 was verified by reverse transcriptase-polymerase chain reaction 
(RT-PCR). 
For transient expression, the transfection of plasmids into HEK293 cells was performed by using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. Briefly, HEK293 cells 
seeded at a density of 2.5-3.5 or 1.2-1.5 × 105 cells per well in a poly-D-lysine coated 12- or 24-well 
plate, respectively, were cultured in DMEM supplemented with 10% FBS and non-essential amino 
acids and the cells were transfected with complexes of 1.2 or 0.6 μg of plasmid and 2 or 1 μl of 
Lipofectamine 2000 reagents diluted in OPTI-MEM I (Invitrogen) in 12- or 24-well plate. At 1 day 
prior to assays, cells were treated with sodium butyrate to enhance the expression of OATP1B1 
proteins. HEK293 cells transfected with the pcDNA3.1 vector alone were used to obtain background 
activity. The expression of OATP1B1 was verified by quantitative real-time PCR analysis after 
treatment of reverse transcriptase reaction. 
 
Inhibition assays 
 
HEK293 cells stably expressing OATP1B1 (HEK293/OATP1B1 cells) and HEK293/mock cells 
were seeded at a density of 2-3 × 105 cells per well in a poly-D-lysine coated 24-well plates, then 
sodium butyrate was added at 1 day prior to assays. The medium was changed to DMEM free from 
both antibiotics and serum. To assess inhibitory effect of chemotherapy agents on typical substrates 
transport mediated by OATP1B1, the medium was removed and the same medium containing both a 
substrate and a various concentration of inhibitor was added. Concentrations of substrates were set at 
500 and 50 nM for [3H] estradiol 17β-D-glucuronide and [3H] estrone 3-sulfate, respectively. The 
monolayers were incubated for 3 min, and then cells were rapidly washed four times with ice-cold 
DMEM. Cells were lysed in 250 μl of 0.2% SDS, and 200-μl aliquots were transferred to 
scintillation vials and 5-μl aliquots of cell lysate were used to determine protein concentrations by 
the method of Lowry with bovine serum albumin (BSA) as a standard. Radioactivity was measured 
by a liquid scintillation counter (LSC 6100, Aloka Co., Tokyo, Japan). The uptake rate was estimated 
by subtracting uptake by HEK293/mock cells from total uptake by HEK293/OATP1B1 cells and was 
expressed as a percentage of that obtained in the absence of inhibitor (control). IC50 value, inhibitor 
concentration at which half the maximal uptake of substrate was inhibited, was calculated by 
inhibitory effect Emax model using WinNonlin (Pharsight, Inc., Mountain View, CA).  
 
Quantitative real-time PCR analysis 
 
Total RNA was extracted by using RNeasy kit (Qiagen) in combination with the RNase-free 
DNase-treatment to minimize plasmid contamination from transfected cells that had been exposed to 
sodium butyrate for 1 day. Synthesis of cDNA was performed by using SuperScript III reverse 
transcriptase (Invitrogen) with oligo d(T)20 primers (Invitrogen) and RNaseOUT (Invitrogen) 
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according to the manufacturer’s protocol. Then, the quantitative real-time PCR  reaction was 
performed by using TaqMan reagents, targeting for OATP1B1 and glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH), with 7500 Fast system (Applied Biosystems) according to the 
manufacturer’s protocol. Relative quantitation of mRNA expression of OATP1B1 to GAPDH was 
estimated by the comparative threshold cycle (Ct) method (ddCt). The relative expression level of 
each variant was normalized by that of OATP1B1*1a. 
 
Transport assays 
 
Substrate concentrations of test compounds were determined from inhibition assays. 
Concentrations of melphalan, anthracyclines, camptothecins, etoposide, vincaalkaloids, docetaxel, 
paclitaxel, bicalutamide and flutamide were set at 10, 2, 5, 5, 1, 1, 0.02, 2 and 10 μM in order to 
make their concentrations lower than IC50 values. Methotrexate concentration was set at 10 μM since 
Km value, half the maximal uptake concentration, was expected to be higher than 100 μM. 
For 3H- and 14C-labeled substrates, the transfected cells in 24-well plates were treated with 
sodium butyrate for 1 day. The medium was changed to DMEM free from both antibiotics and serum 
without a substrate. To assess transporting activity, the medium was removed and the same medium 
containing a substrate was added. The monolayers were incubated for 2 min, and then cells were 
rapidly washed once or twice with ice-cold DMEM containing 5% FBS and three times with ice-
cold DMEM. Cells were lysed in 250 μl of 0.2% SDS, and 200-μl aliquots were transferred to 
scintillation vials and 5-μl aliquots of cell lysate were used to determine protein concentrations as 
described above. Radioactivity was measured as described above. 
For un-radiolabeled substrates, the transfected cells in 12-well plates were treated with sodium 
butyrate for 1 day. The medium was changed to DMEM free from both antibiotics and serum 
without a substrate. To assess transporting activity, the medium was removed and the same medium 
containing a substrate was added. The monolayers were incubated for 2 or 3 min depending on 
substrates, and then cells were rapidly washed once or twice with ice-cold DMEM containing 5% 
FBS and three times with ice-cold DMEM. Ice-cold extraction solution (500 μl) consisting of acetic 
acid-acetonitrile-methanol-water (1:25:25:50, v/v/v/v) was added, and the extraction solution 
containing cells was transferred to a centrifuge tube and then the substrate accumulated in cells was 
extracted by sonication for 10 min at 4°C. After centrifugation at 17,000 × g for 10 min at 4°C, a 
400-μl aliquot of the supernatant was transferred to MultiScreen Solvinert (Millipore, Billerica, MA) 
and filtered by centrifugation at 750 × g for 5 min at 4°C. The obtained filtrates were injected into 
HPLC tandem mass spectrometry (LC-MS/MS). To the cell pellet, 400 μl of 0.1N NaOH was added 
and solubilized, and then a 5-μl aliquot of cell lysate was used to determine protein concentration as 
described above. 
The uptake rate was calculated as cell-to-medium ratio, which was estimated by dividing the 
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amount of compounds accumulated in cells by the substrate concentration in the transport medium. 
 
Analytical procedures for un-radiolabeled substrates 
 
Quantification of un-radiolabeled substrates was performed using LC-MS/MS. The HPLC 
system consisted of three LC-10ADVP pumps, a SLC-10AVP controller, a SIL-HTC auto-injector 
and a FCV-12AH switching valve (Shimadzu, Kyoto, Japan). The HPLC column used was a 
CAPCELL PAK C18 MG II (5 μm in particle size, 3.0 × 35 mm, Shiseido, Tokyo, Japan). Aliquots 
(2-50 μl) of samples were injected onto the column with the mixture of water-acetonitrile-methanol-
acetic acid (900:50:50:1; v/v/v/v) (eluate A) and water-acetonitrile-methanol-acetic acid 
(100:450:450:1; v/v/v/v) (eluate B) at a flow rate of 0.5 ml/min using a gradient program described 
below, and the eluate was taken into the mass spectrometer between 2.1 min and 4.5 min. The time 
program of the mixture ratio of eluate A and eluate B was set as follows: 0% B for 0.0-1.0 min, 
linear gradient from 0 to 100% B for 1.0-2.0 min, 100% B for 2.0-2.5 min, linear gradient from 100 
to 0% B for 2.5-2.6 min, and then 0% B for 2.6-7.0 min. The analytes were detected by an API4000 
mass spectrometer with a turbo-ion spray interface (Applied Biosystems). Analytical methods were 
summarized in Table 1. 
 
Table 1.  Anticancer agents used in this study and their analytical methods 
Monitoring ion (m/z) Category / Compound Detection Method a 
Ionization 
(polarity) IS 
b precursor product 
Quantitation 
range (nM) 
(A) Metabolic competitors      
 Ara-C -      
 5-FU -      
 Mercaptopurine -      
 Methotrexate LC-MS/MS ESI(+) PHC 455.2 308.2 0.5-200 
(B) Alkylation agents       
 Cyclophosphamide -      
 Ifosfamide -      
 Melphalan LC-MS/MS ESI(+) PHC 305.2 288.1 0.5-200 
(C) Platinum agents       
 Carboplatin -      
 Cisplatin -      
a LC-MS/MS, HPLC tandem mass spectrometry. 
b Precursor and product ions of internal standards (IS), phenacetin (PHC), m/z 180.3 and 110.1. 
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Table 1.  (Continued) 
Monitoring ion (m/z) Category / Compound Detection Method a 
Ionization 
(polarity) IS 
b precursor product 
Quantitation 
range (nM) 
(D) Antibiotics       
 Amrubicin LC-MS/MS ESI(+) PHC 484.4 333.1 0.2-400 
 Bleomycin -      
 Doxorubicin LSC      
 Epirubicin LC-MS/MS ESI(+) PHC 544.4 397.2 0.2-400 
 Mitomycin C -      
(E) Topo I inhibitors       
 SN-38 LC-MS/MS ESI(+) PHC 393.3 349.3 0.2-200 
 Topotecan LC-MS/MS ESI(+) PHC 422.3 377.2 0.2-200 
 Camptothecin LC-MS/MS ESI(+) PHC 349.3 305.4 0.2-200 
(F) Topo II inhibitor       
 Etoposide LSC      
(G) Vincaalkaloids       
 Vinblastine LSC      
 Vincristine LSC      
 Vinorelbine LC-MS/MS ESI(+) PHC 779.5 658.6 0.5-200 
(H) Taxanes       
 Docetaxel LC-MS/MS ESI(+) - 808.6 226.1 2-100 
 Paclitaxel LSC      
(I) Antiandrogen agents      
 Bicalutamide LC-MS/MS ESI(-) OHF 429.0 255.1 5-500 
 Flutamide LC-MS/MS ESI(-) OHF 275.0 202.0 5-500 
(J) Antiestrogen agents       
 Tamoxifen -      
 Toremifene -      
a LSC, liquid scintillation counting; LC-MS/MS, HPLC tandem mass spectrometry. 
b Precursor and product ions of internal standards (IS), phenacetin (PHC), m/z 180.3 and 110.1; OH-flutamide (OHF), 
291.0 and 205.0. 
 
 
II-III: Results 
 
Inhibition screening of anticancer agents on OATP1B1-mediated transport of typical 
substrates 
 
Inhibition screening of 30 structurally different anticancer agents on the transport of 
estradiol 17β-D-glucuronide and estrone 3-sulfate were performed by using stably 
OATP1B1 expressing system. Concentration-dependent inhibitory effect was observed 
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(A) Metabolic competitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) Alkylation agents 
 
 
 
 
 
 
 
(C) Platinum agents 
 
 
 
 
 
 
 
Fig. 1.  Inhibitory effects of anticancer agents on [3H] estradiol 17β-glucuronide (●) and [3H] 
estrone 3-sulfate (○) uptake into HEK293/OATP1B1 cells. 
Uptake of estradiol 17β-glucuronide (500 nM) or estrone 3-sulfate (50 nM) were measured for 3 min and the results 
are shown as a percentage of control uptake measured in the absence of inhibitors after correcting for the uptake by 
the mock cells. Each point represents the mean and S.D. from three or more determinations. Solid line and dotted line 
represent fitting lines calculated by inhibitory effect Emax model using WinNonlin for estradiol 17β-glucuronide and 
estrone 3-sulfate, respectively. 
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in 15 out of 30 compounds. Calculated IC50 values were summarized in Table 2. 
Metabolic competitors including methotrexate, which is known to be a substrate for 
OATP1B1, did not show the apparent inhibition on uptake of typical substrates (Fig. 
1A). Among the alkylation agents, melphalan showed the concentration-dependent 
inhibition, and inhibition of ifosfamide on the estrone 3-sulfate transport was not clear 
as the inhibitory effects at 30 and 100 μM were not different (Fig. 1B). Any interactions 
were not observed in platinum agents, such as carboplatin and cisplatin (Fig. 1C). All of 
examined anthracyclines inhibited the OATP1B1-mediated uptake of estradiol 17β-D-
glucuronide in a dose-dependent manner, however, their inhibitory effects on estrone 3-
sulfate uptake were obviously weaker (Fig. 1D). Influence of amrubicin on the uptake 
of estrone 3-sulfate was unique as inhibitory and stimulant effects were observed at 
lower and higher concentration, respectively. Type I DNA topoisomerases (Topo I) 
 
(D) Antibiotics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.  (Continued) 
 
inhibitors, camptothecin derivatives, exhibited the concentration-dependent inhibition in 
acid form, while those in lactone form did not (Fig. 1E). Both etoposide, Topo II 
inhibitor, and vincaalkaloids inhibited the uptake of typical substrates in a dose-
dependent manner, however, the inhibitory effect on estrone 3-sulfate uptake was 
obviously weaker than that on estradiol 17β-D-glucuronide uptake (Fig. 1F-G). Both of 
taxanes, docetaxel and paclitaxel, strongly inhibited the uptake of typical substrates (Fig. 
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1H). The profile of inhibitory effects on the uptake of typical substrates were different 
between docetaxel and paclitaxel, as the former inhibited estradiol 17β-D-glucuronide 
uptake more strongly than estrone 3-sulfate uptake while the latter inhibited both 
 
(E) Topo I inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(F) Topo II inhibitor 
 
 
 
 
 
 
 
(G) Vincaalkaloids 
 
 
 
 
 
 
 
 
Fig. 1.  (Continued) 
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substrates almost equally. Both of antiandrogen agents, bicalutamide and flutamide, 
inhibited the uptake of typical substrates, and their inhibitory effects of estrone 3-sulfate 
uptake were weaker than those of estradiol 17β-D-glucuronide (Fig. 1I). No inhibitory 
effect was observed in antiestrogen agents (Fig. 1J). 
 
(H) Taxanes 
 
 
 
 
 
 
 
 
(I) Antiandrogen agents 
 
 
 
 
 
 
 
 
(J) Antiestrogen agents 
 
 
 
 
 
 
 
 
Fig. 1.  (Continued) 
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Table 2. IC50 values of anticancer agents and their pharmacokinetics parameters reported previously 
IC50 (μM) b Cmax Cmax,u Compound a  E217βG E1S (μM) 
fu (μM) 
Ara-C  – –    
5-FU  – –    
Mercaptopurine  – –    
Methotrexate  – –    
Cyclophosphamide  – –    
Ifosfamide  – –    
Melphalan  64.0 – 69 d 0.71-0.8 [39] 49-55 
Carboplatin  – –    
Cisplatin  – –    
Amrubicin  79.9 – 7.5 [40] 0.03 d 0.23 
Bleomycin  – –    
Doxorubicin  32.8 167 >100 d 0.24 [41] >24 
Epirubicin  55.3 20.0 6.3 [42] 0.23 [43] 1.4 
Mitomycin C  – –    
SN-38       
  Acid  14.4 78.0 0.067 e [44] N/A <0.067 
  lactone  – –    
Topotecan       
  Acid  166 – 0.19 d,e N/A <0.19 
  lactone  – –    
Camptothecin c       
  Acid  18.4 N/E    
  lactone  – –    
Etoposide  41.2 – 31 [45] 0.04 [39] 1.2 
Vinblastine  4.27 16.9 >0.11 d <0.01 [39] Approx. 0.0011 
Vincristine  6.51 67.4 >0.065 d 0.25 f Approx. 0.016 
Vinorelbine  19.7 119 1.0 [46] 0.12 [39] 0.12 
Docetaxel  1.70 14.5 2.8 [47] 0.012-0.23 [48] 0.034-0.64 
Paclitaxel  0.263 0.342 5.1 [49] 0.094-0.12 d 0.48-0.61 
Bicalutamide  11.2 25.6 1.9 [50] 0.04 [51] 0.076 
Flutamide  47.3 192 0.41 [52] 0.04-0.06 f 0.016-0.025 
Tamoxifen  – –    
Toremifene  – –    
a Concentrations of inhibitors were typically set at 3, 10, 30 and 100 μM but for Ara-C (10, 30, 100 and 300 μM) and 
taxanes (0.03, 0.1, 0.3, 1, 3, 10, 30 and 100 μM). 
b –, IC50 was greater than 200 μM. 
c Not clinically used as a drug. 
d Data from ethical drug package insert. 
e Total concentration of lactone and acid. 
f The Pharmacogenetics and Pharmacogenomics Knowledge Base at web site, http://www.pharmgkb.org/index.jsp. 
Abbreviations, fu, unbound fraction in plasma; Cmax,u, maximum unbound plasma concentration; N/A, not available; 
N/E, not examined. 
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Quantitative real-time PCR analysis 
 
Quantitative real-time PCR analysis was performed in cells transfected with 
plasmids with or without an insert of OATP1B1*1a, *1b or *15 cDNA. The extents of 
OATP1B1 mRNA expression level relative to GAPDH mRNA level were not different 
among these variants (Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.  Real time PCR assays for OATP1B1 mRNA expression relative to GAPDH using 
transient expression system. 
Each bar represents the mean and S.D. of three independent experiments conducted in duplicate. Values in 
parentheses represent percent of expression levels relative to OATP1B1*1a. 
 
Uptake assay of the potent inhibitors by OATP1B1 
 
To examine whether the potent inhibitors become substrates for OATP1B1, uptake 
study was performed by using the transient expression system. When the tendency of 
uptake by OATP1B1 was observed, effect of polymorphisms was also evaluated by 
transfection of OATP1B1*15 expression vectors in addition to OATP1B1*1a and *1b 
expression vectors. The results of uptake experiments were shown in Fig. 3. As reported 
by Abe et al. [36] and Tirona et al. [12], it was confirmed that methotrexate was a good 
substrate for OATP1B1*1a as well as *1b. Melphalan, derivative of phenylalanine, was 
not effectively transported by OATP1B1, although it contained functional moiety of 
carboxylic acid. Among anthracyclines, significant uptake by OATP1B1*1a was 
observed in doxorubicin. Neither amrubicin nor epirubicin were effectively transported 
by OATP1B1, though their structures were similar with doxorubicin. Among Topo I 
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Fig. 3.  Uptake of anticancer agents into HEK293 cells transiently transfected with 
OATP1B1*1a, *1b, *15 or empty vectors (mock). 
Each bar represents mean and S.D. of three or four independent assays conducted in duplicate or triplicate. *, P < 
0.05; **, P < 0.01; ***, P < 0.001 versus mock above each bar or among variants above bars for analysis object by 
the Student’s t-test. N.S., not significantly different. 
 
inhibitors, significant uptake by OATP1B1*1a and *1b was observed in SN-38 acid and 
camptothecin acid, and the uptake of SN-38 acid was consistent with a result reported 
by Nozawa et al. [25]. The uptake of topotecan acid by OATP1B1*1a and *1b was not 
found although its structure was similar with SN-38 and camptothecin. Etoposide, a 
Topo II inhibitor, was not transported by OATP1B1. Certain OATP1B1-mediated uptake 
was observed in vinorelbine, but not in vinblastine and vincristine. Though taxanes, 
docetaxel and paclitaxel, effectively inhibited the OATP1B1-mediated uptake of typical 
substrates, the accumulation into cells by OATP1B1 was not observed. The 
antiandrogen agents, bicalutamide and flutamide, were not substrates for OATP1B1. 
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Fig. 3.  (Continued) 
Abbreviation, CPT, camptothecin. 
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II-IV: Discussion 
 
The results of the present study using transient expression system of OATP1B1 
showed that doxorubicin, vinorelbine and camptothecin acid were found to be novel 
substrates for OATP1B1 and confirmed that methotrexate and SN-38 acid was 
transported by OATP1B1 as previous reported [12,24,36]. With regard to the effect of 
polymorphisms on transporting activity, no significant difference was found between 
OATP1B1*1a and *1b in doxorubicin, vinorelbine, camptothecin acid and SN-38 acid 
and disappearance of transporting activity was observed in OATP1B1*15 variant. 
Eleven other inhibitors were not effectively transported by OATP1B1 even though the 
interaction with OATP1B1 was strong enough to inhibit the uptake of typical substrates. 
Since the contribution of the transporter-mediated uptake to the total membrane 
permeability is depending on the sum of passive diffusion and active transport including 
uptake and efflux, these factors should be discussed to evaluate the impact of the 
present findings on the clinical use of drugs. The uptake rate into HEK293/mock cells 
(Pmock) might be the representative parameter for passive diffusion. Ratios of OATP1B1-
mediated uptake rate to Pmock of doxorubicin and vinorelbine were lower than those of 
methotrexate and SN-38 acid. In addition, the uptake process would not be the rate 
limiting step of the hepatic clearance if permeability-surface area product by passive 
diffusion was much higher than intrinsic clearance of metabolism and/or biliary 
excretion [1,2]. Since Pmock values of doxorubicin and vinorelbine (41.1 and 98.6 
μl/min/mg protein) were much higher than those of methotrexate and SN-38 acid (0.260 
and 2.55 μl/min/mg protein), both doxorubicin and vinorelbine would rapidly penetrate 
from blood to hepatocytes by passive diffusion. These contention suggest that 
polymorphisms in the SLCO1B1 gene would not efficiently affect the pharmacokinetics 
of doxorubicin and vinorelbine since the less contribution of OATP1B1-mediated 
transport to the total membrane permeability and rapid penetration across the cell 
membrane were expected in those substrates. However, further in vivo studies are 
needed to evaluate the contribution of OATP1B1 and its variants to the total clearance 
of doxorubicin, vinorelbine and methotrexate as well as irinotecan. 
Surprisingly, 15 out of 30 anticancer agents showed inhibitory effects on the 
transport of estradiol 17β-D-glucuronide and/or estrone 3-sulfate in a concentration-
dependent manner. This result suggests that OATP1B1 indeed recognizes structurally 
wide variety of compounds. Since potent inhibitors of melphalan, etoposide, 
bicalutamide and flutamide are orally administrated in clinical use, it is important to 
evaluate the possibility of drug-drug interaction of these agents. When IC50 values of 
these drugs are compared with their maximum unbound plasma concentrations (Cmax,u), 
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melphalan could be a perpetrator as level of those parameters was almost equivalent. In 
addition, both doxorubicin and paclitaxel could be perpetrators on OATP1B1-mediated 
uptake, as IC50 values of these drugs were also comparable to Cmax,u. Therefore, it 
should be notable that melphalan, doxorubicin and paclitaxel might increase exposure 
level of concomitant drugs, when OATP1B1-mediated uptake was a rate-limiting step 
for concomitant drugs. 
It was of interest that the multiple effects of inhibitors were observed on the uptake 
of estradiol 17β-D-glucuronide and estrone 3-sulfate. Since many inhibitors showed 
different IC50 values between estradiol 17β-D-glucuronide and estrone 3-sulfate, it was 
possible that estradiol 17β-D-glucuronide interacted with OATP1B1 at a different site 
from that for estrone 3-sulfate. Our finding that amrubicin showed inhibitory and 
stimulant effects on OATP1B1-mediated estrone 3-sulfate uptake at low and high 
concentration, respectively, further indicates the possibility. Sugiyama et al. [53] 
reported that effects of estradiol 17β-D-glucuronide on rat oatp2-mediated uptake of 
digoxin and taurocholate were inhibitory and stimulant manner, respectively, suggesting 
that estradiol 17β-D-glucuronide interacted with rat oatp2 at a different site from that 
for taurocholate and digoxin. Together, although the mechanism by which the uptake of 
OATP1B1 was stimulated not clear, these findings suggest that OATP1B1 have multiple 
binding sites, that exist either in the substrate recognition site or the transport activity-
affecting sites, which is present out of substrate binding domain. Considering this 
suggestion, it should be noticed that the ‘false negative’ results may be given with an 
inhibition assay performed by using only one substrate to evaluate whether test 
compounds become substrates for OATP1B1. 
Configuration of charge in camptothecin derivatives may be of importance to assess 
the structure-substrate recognition relationship. Carboxylic acid moiety at E ring should 
play a major role in substrate recognition by OATP1B1 because lactone form of 
camptothecin, as well as SN-38, was not effectively transported by OATP1B1 (data not 
shown). Topotecan acid, however, was not a good inhibitor and/or substrate for 
OATP1B1 though chemical structure was quite similar with camptothecin and SN-38. It 
was suggested that the steric effect and/or positive charge at A ring of camptothecin 
structure may be important for interaction at the substrate recognition site(s). To discuss 
the structure-substrate recognition relationship, more data of camptothecin derivatives 
should be provided. 
In conclusion, the results of current study show that a half of examined structurally-
diverse anticancer agents have the potency of inhibition for OATP1B1-mediated uptake 
of typical endogenous substrates. Among these inhibitors, melphalan, doxorubicin and 
paclitaxel seem to be perpetrators on drug-drug interaction at OATP1B1 since IC50 
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values are comparable with Cmax,u. In addition, doxorubicin and vinorelbine could be 
novel substrates for OATP1B1. Since the involvement of OATP1B1 in hepatic uptake of 
these chemotherapeutic agents might be limited in the total penetration, further in vivo 
studies are needed to evaluate the contribution of OATP1B1 to the total clearance of 
doxorubicin and vinorelbine as well as methotrexate and irinotecan. 
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Conclusion 
1. The SNP c.521T>C was found to reduce its transporting activity for 
estradiol 17β-D-glucuronide, estrone 3-sulfate, pravastatin, atorvastatin 
and cerivastatin, but not for simvastatin. Mutations of c.388A>G or 
c.1007C>G did not remarkably alter the transporting activity of 
OATP1B1. Atorvastatin was found as a novel substrate for OATP1B1. 
 
2. Kinetic analysis of OATP1B1-mediated uptake of pravastatin and 
atorvastatin suggests that decrease of intrinsic clearance for OATP1B1 
variants containing c.521T>C is due to the decline in the transporting 
function of OATP1B1, but not decreasing affinity to substrate-
recognition site of OATP1B1. 
 
3. Immunocytochemical analysis revealed that c.521T>C lead to impaired 
membrane targeting of OATP1B1 protein in both HeLa and HEK293 
cells, which would be the main reason for the reduction of Vmax values 
of the statins uptake. Thus, c.521T>C is the key SNP that causes a 
sorting error of OATP1B1 and decreases the functional activity of 
variant proteins derived from SLCO1B1*5, *15 and *15+C1007G. 
 
4. Fifteen out of 30 anticancer agents were the potent inhibitors for 
OATP1B1, and melphalan, doxorubicin and paclitaxel could be 
perpetrators on drug-drug interaction at OATP1B1 since IC50 values are 
comparable to their maximum unbound plasma concentrations. 
 
5. Doxorubicin, vinorelbine and camptothecin acid were novel substrates 
for OATP1B1. Twelve other inhibitors, except for SN-38 acid, were not 
effectively transported by OATP1B1. Marked difference between 
OATP1B1*1a and *1b uptake did not exist and the OATP1B1-mediated 
uptake mostly disappeared in OATP1B1*15 variant for these substrates. 
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